Abstract
For more than a century, Chagas Disease is one of the most epidemiological significant disease in Brasil, and nowadays it still remains neglected by the global pharmaceutical industries, that invest primarily on the development of new drugs for the treatment of globally more incident pathologies, mainly those that afflict the developed countries, in order to guaranty the monetary returns …